X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (1113) 1113
humans (935) 935
mianserin - pharmacology (890) 890
animals (851) 851
pharmacology & pharmacy (761) 761
mianserin - analogs & derivatives (692) 692
female (623) 623
rats (577) 577
mianserin - therapeutic use (517) 517
mianserin (513) 513
psychiatry (483) 483
adult (471) 471
mirtazapine (427) 427
neurosciences (363) 363
middle aged (362) 362
mianserin - adverse effects (325) 325
index medicus (317) 317
antidepressants (286) 286
antidepressive agents - pharmacology (247) 247
aged (235) 235
depressive disorder - drug therapy (221) 221
antidepressive agents, tricyclic - therapeutic use (216) 216
dose-response relationship, drug (215) 215
clinical neurology (198) 198
serotonin (198) 198
mianserin - administration & dosage (184) 184
serotonin antagonists - pharmacology (183) 183
antidepressive agents, tricyclic - pharmacology (182) 182
depression (180) 180
double-blind method (180) 180
rats, inbred strains (164) 164
time factors (152) 152
treatment outcome (145) 145
receptors, serotonin - drug effects (142) 142
dibenzazepines - pharmacology (141) 141
mice (138) 138
major depression (136) 136
psychiatric status rating scales (134) 134
antidepressive agents, tricyclic - adverse effects (133) 133
depression - drug therapy (128) 128
antidepressant (127) 127
drug interactions (120) 120
double-blind (115) 115
fluoxetine (114) 114
in vitro techniques (113) 113
amitriptyline (111) 111
rats, wistar (109) 109
brain - metabolism (108) 108
depressive disorder, major - drug therapy (108) 108
rats, sprague-dawley (107) 107
behavior, animal - drug effects (104) 104
receptors (104) 104
serotonin - metabolism (102) 102
antidepressive agents - therapeutic use (98) 98
mianserin - metabolism (98) 98
amitriptyline - pharmacology (96) 96
drug therapy, combination (96) 96
serotonin - pharmacology (95) 95
adolescent (93) 93
imipramine - pharmacology (93) 93
brain (89) 89
clinical trials as topic (88) 88
motor activity - drug effects (87) 87
brain - drug effects (86) 86
efficacy (83) 83
kinetics (83) 83
mianserin - blood (83) 83
rat (83) 83
adrenergic alpha-antagonists - pharmacology (80) 80
dopamine (77) 77
mianserin - pharmacokinetics (75) 75
desipramine - pharmacology (74) 74
receptors, serotonin - metabolism (73) 73
antidepressive agents, tricyclic - administration & dosage (72) 72
drugs (72) 72
5-ht (71) 71
depressive disorder - psychology (70) 70
imipramine (66) 66
pharmacology (66) 66
norepinephrine - metabolism (65) 65
venlafaxine hydrochloride (65) 65
placebo (64) 64
serotonin uptake inhibitors - therapeutic use (63) 63
cerebral cortex - metabolism (62) 62
analysis of variance (61) 61
serotonin - physiology (61) 61
rat-brain (60) 60
aged, 80 and over (59) 59
schizophrenia (59) 59
antidepressive agents, second-generation - therapeutic use (58) 58
antidepressive agents - adverse effects (57) 57
dibenzazepines - therapeutic use (57) 57
receptors, serotonin - physiology (57) 57
serotonin uptake inhibitors - pharmacology (57) 57
stereoisomerism (57) 57
psychology (56) 56
major depressive disorder (55) 55
paroxetine (55) 55
venlafaxine (55) 55
anxiety (51) 51
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1859) 1859
Japanese (23) 23
German (10) 10
Russian (7) 7
French (5) 5
Hungarian (4) 4
Spanish (4) 4
Dutch (3) 3
Polish (3) 3
Bulgarian (1) 1
Danish (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuroendocrinology Letters, ISSN 0172-780X, 2010, Volume 31, Issue 5, pp. 645 - 656
Journal Article
Psychopharmacology, ISSN 0033-3158, 8/2016, Volume 233, Issue 15, pp. 2955 - 2971
Fas-associated death domain (FADD) is an adaptor of death receptors that can also induce anti-apoptotic actions through its phosphorylated form (p-FADD).... 
Neuroplasticity | Neuroprotection | Neurosciences | Biomedicine | FADD and p-FADD | Forced swim test | Anti-depressant drugs | Pharmacology/Toxicology | Psychiatry | Electroconvulsive shock | PRESYNAPTIC AUTORECEPTORS | NEUROTRANSMITTER RELEASE | PSYCHIATRY | ANTIDEPRESSANT TREATMENT | ADRENERGIC-RECEPTOR | MAJOR DEPRESSION | SUICIDE VICTIMS | NEUROSCIENCES | PREFRONTAL CORTEX | MONOAMINE-OXIDASE INHIBITORS | PHARMACOLOGY & PHARMACY | GAMMA-AMINOBUTYRIC-ACID | DEATH DOMAIN PROTEIN | Phosphoproteins - drug effects | Phenelzine - pharmacology | Autoreceptors - metabolism | Clorgyline - pharmacology | Male | Adrenergic alpha-Antagonists - pharmacology | Phosphoproteins - metabolism | Cerebral Cortex - metabolism | Idazoxan - pharmacology | Mianserin - analogs & derivatives | Mianserin - pharmacology | Desipramine - pharmacology | Fluoxetine - analogs & derivatives | Mirtazapine | Antidepressive Agents - pharmacology | Cerebral Cortex - drug effects | Phosphorylation - drug effects | RNA-Binding Proteins - antagonists & inhibitors | Fluoxetine - pharmacology | Idazoxan - analogs & derivatives | Monoamine Oxidase Inhibitors - pharmacology | Fas-Associated Death Domain Protein - drug effects | Norepinephrine Plasma Membrane Transport Proteins - antagonists & inhibitors | Fas-Associated Death Domain Protein - metabolism | Rats | Excitatory Amino Acid Antagonists - pharmacology | Blotting, Western | Brain - drug effects | Animals | CASP8 and FADD-Like Apoptosis Regulating Protein | Thiazoles - pharmacology | Ketamine - pharmacology | Electroshock | Apoptosis | Indans - pharmacology | Pharmacology, Experimental | Antidepressants | Desipramine | Fluoxetine | Psychopharmacology | Dosage and administration | Research
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 12/2017, Volume 234, Issue 23, pp. 3507 - 3520
Racemic (RS)-amisulpride (Solian®) is an atypical antipsychotic drug used to treat schizophrenia and dysthymia. Blockade of dopamine D2/D3 and/or serotonin... 
Drug discrimination | Neurosciences | Amisulpride | Schizophrenia | Isomers | Anxiolytics | Discriminative stimulus | Antipsychotics | Biomedicine | Antidepressants | C57BL/6 mice | Benzamides | Pharmacology/Toxicology | Psychiatry | CORTICAL MEMBRANES | PSYCHIATRY | HIGH-AFFINITY | MAJOR DEPRESSION | D-2 RECEPTORS | NEUROSCIENCES | RECEPTOR ANTAGONIST | LIMBIC SELECTIVITY | 5-HT7 RECEPTOR | PHARMACOLOGY & PHARMACY | MOLECULAR-CLONING | RAT-BRAIN | DOPAMINE-RECEPTORS | Sulpiride - pharmacology | Conditioning, Operant - physiology | Male | Sulpiride - analogs & derivatives | Clozapine - pharmacology | Discrimination Learning - drug effects | Clozapine - chemistry | Conditioning, Operant - drug effects | Antidepressive Agents - chemistry | Anti-Anxiety Agents - chemistry | Antidepressive Agents - pharmacology | Benzamides - pharmacology | Quetiapine Fumarate - pharmacology | Benzamides - chemistry | Quetiapine Fumarate - chemistry | Mice, Inbred C57BL | Chlorpromazine - chemistry | Risperidone - pharmacology | Anti-Anxiety Agents - pharmacology | Chlorpromazine - pharmacology | Risperidone - chemistry | Discrimination Learning - physiology | Animals | Antipsychotic Agents - chemistry | Mice | Antipsychotic Agents - pharmacology | Sulpiride - chemistry | Dosage and administration | Antipsychotic drugs | Comparative analysis | Drug interactions | Antianxiety agents | Stereoisomers | Drugs | Neuroleptics | Olanzapine | Operant conditioning | Mental disorders | Aripiprazole | Benzamide | Metoclopramide | Chlorpromazine | Sulpiride | Serotonin S7 receptors | Psychotropic drugs | Imipramine | Receptors | Bupropion | Mianserin | Risperidone | Dopamine D2 receptors | Drug dosages | Quetiapine | Raclopride | Dopamine | Serotonin | Dopamine D3 receptors | Chlordiazepoxide | Pharmacology | Clozapine | Derivatives | Properties (attributes) | Serotonin receptors
Journal Article
Neuroscience, ISSN 0306-4522, 2005, Volume 131, Issue 3, pp. 717 - 731
The olfactory bulb, first relay of olfactory pathways, is densely innervated by serotoninergic centrifugal fibers originating from the raphe nuclei. Although... 
5HT | 5HT 2A receptors | 5HT 2C receptors | olfactory bulb | rat | whole-cell recordings | Olfactory bulb | receptors | Rat | Whole-cell recordings | 5HT(2A) receptors | RETROGRADE AXONAL-TRANSPORT | SEROTONERGIC MODULATION | 5HT(2C) receptors | 5-HT2A RECEPTOR | NEUROSCIENCES | CEREBRAL-CORTEX | DEFINED NEURON GROUPS | NERVE-TERMINALS | GLOMERULAR LAYER | RECIPROCAL SYNAPSES | NEONATE RAT | ACTIVATED CATION CURRENT | Free Radical Scavengers - pharmacology | Rats, Wistar | Electrophysiology | Membrane Potentials - radiation effects | Methysergide - pharmacology | Apamin - pharmacology | Serotonin - pharmacology | Patch-Clamp Techniques - methods | Mianserin - pharmacology | Neurons - classification | Olfactory Pathways - physiology | Drug Interactions | Kynurenic Acid - pharmacology | Neurons - drug effects | Nickel - pharmacology | Olfactory Pathways - drug effects | Electric Stimulation - methods | 4-Aminopyridine - pharmacology | Potassium Channel Blockers - pharmacology | Olfactory Bulb - cytology | Animals, Newborn | Membrane Potentials - drug effects | Benzodiazepines - pharmacology | Chlorides - pharmacology | Rats | Logistic Models | Excitatory Amino Acid Antagonists - pharmacology | Bicuculline - pharmacology | Membrane Potentials - physiology | Serotonin Antagonists - pharmacology | GABA Antagonists - pharmacology | Cesium - pharmacology | Animals | In Vitro Techniques | Olfactory Pathways - radiation effects | Dose-Response Relationship, Radiation | Olfactory Bulb - drug effects
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 12/1998, Volume 18, Issue 23, pp. 10150 - 10156
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 8/2018, Volume 235, Issue 8, pp. 2423 - 2434
Journal Article
Journal Article
CNS Neuroscience & Therapeutics, ISSN 1755-5930, 12/2011, Volume 17, Issue 6, pp. 723 - 732
SUMMARY Even though noradrenaline has been recognized as one of the key neurotransmitters in the pathophysiology of major depression (MD), noradrenergic... 
Noradrenergic compounds | Major depression | Noradrenaline | EFFICACY | DEFICIT HYPERACTIVITY DISORDER | NEUROSCIENCES | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | NOREPINEPHRINE REUPTAKE INHIBITOR | BUPROPION | ATYPICAL DEPRESSION | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSIVE DISORDER | ANXIETY DISORDERS | EXTENDED-RELEASE | Monoamine Oxidase Inhibitors - pharmacology | Synaptic Transmission - physiology | Dopamine Uptake Inhibitors - pharmacology | Norepinephrine - physiology | Sympathetic Nervous System - drug effects | Humans | Behavior - physiology | Sympathetic Nervous System - metabolism | Antidepressive Agents - therapeutic use | Animals | Norepinephrine - metabolism | Serotonin Agents - pharmacology | Antidepressive Agents, Tricyclic - pharmacology | Psychotropic Drugs - pharmacology | Adrenergic Uptake Inhibitors - pharmacology | Synaptic Transmission - drug effects | Antidepressive Agents - pharmacology | Antipsychotic Agents - pharmacology | Serotonin Uptake Inhibitors - pharmacology | Oxidases | Nortriptyline | Metabolites | Desipramine | Art schools | Antidepressants | Attention-deficit hyperactivity disorder | Dopamine | Attention deficit hyperactivity disorder | Motor activity | Central nervous system | mianserin | Depression | Serotonin uptake inhibitors | Amine oxidase (flavin-containing) | Play | Clinical aspects | Neurotransmitters | Reviews | Arousal | Norepinephrine | bupropion | reboxetine
Journal Article